Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus PROMETH FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus PROMETH FORTIS.
HISTAFED vs PROMETH FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, with additional anticholinergic, antiemetic, and sedative properties. It blocks histamine at H1 receptors, reducing allergic symptoms and motion sickness, and exerts antiemetic effects by blocking dopamine D2 receptors in the chemoreceptor trigger zone.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
Adults: 12.5-25 mg intramuscular or intravenous every 4-6 hours as needed for nausea. For severe nausea up to 50 mg IM/IV. Maximum single dose 50 mg, maximum daily dose 200 mg.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life: 9–16 hours (mean ~12 hours). In children and elderly, half-life may be prolonged (up to 20 hours).
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Primarily renal as inactive metabolites; <1% excreted unchanged. Total elimination: renal ~70%, fecal ~30%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine